Media.Player

Anti-KLK8

总结

Kallikrein-8 as an early biomarker for the prediction and diagnosis of Alzheimer`s disease – even of precursor stages long before clinical symptoms appear.

技术优势

First-in-class therapy approach for AD
For the treatment and prevention of AD
Biomarker for predicting and diagnosing AD – even precursor stages of AD long before clinical symptoms appear
Molecular mode of action largely deciphered

技术应用

KLK8 is a potential (early) biomarker for the diagnosis of for Alzheimer’s disease. Antibody-mediated inhibition of KLK8 is a promising therapeutic approach against for Alzheimer’s disease.

详细技术说明

Four weeks of KLK8 inhibition in a moderate disease stage is sufficient to mitigate multiple features of Alzheimer’s pathology in mice without causing any adverse reactions. Cerebral KLK8 blockade reduces amyloid β (Aβ) pathology by impeding amyloidogenic amyloid-precursor-protein (APP) processing, facilitating Aβ clearance across the blood-brain-barrier and boosting microglial Aβ phagocytosis and autophagy, resulting in decreased Aβ plaque burden.
KLK8 inhibition further attenuates tau pathology by suppressing tau phosphorylation signaling and subsequent tau hyperphosphorylation.

合作类型

Licensing

申请日期

02/12/2016 00:00:00

申请号码

EP20160775537 20160921

分类

- international:
A61K39/395; A61P25/28; C07K16/40; G01N33/53
- cooperative:
A61K39/395; A61P25/28; C07K16/40; A61K2039/505; A61K2039/54; A61K9/51; C07K2317/76

其他

Patent application

ID号码

4509

国家/地区

德国